University Hospital, University of Lund
Malmö, Sweden
NCT Number: NCT00344435
This international study will identify genetic factors that may influence the development of inhibitory antibodies in patients with hemophilia A after treatment with factor VIII. Bleeding episodes in patients with inhibitors are often more difficult to treat. Previous research indicates that genetic factors play a role in the development of inhibitors. A better understanding of the influence of genes in this treatment complication may be helpful in predicting, treating or preventing inhibitors.
People in families in which one or more members have severe factor VIII deficiency and one or more have a history of an inhibitor may be eligible for this study. Participants fill out a form with questions about the person's relationship to other family members taking part in the study. Those with hemophilia provide a brief medical history, including hemophilia-related information, inhibitor history and the presence of other conditions such as hepatitis C and HIV. All participants have a blood sample taken for laboratory and research tests.
Looking for future studies?
Notify Me1 year–100 year
All sexes
Observational
Malmö, Sweden
In collaboration with investigators of the Hemophilia Inhibitor Genetic Study (HIGS) multicenter study and the University of Lund, University Hospital, Malmo, Sweden, we propose to assess the role of genetic variants in the process of developing inhibitors to Factor VIII in persons with hemophilia. The discovery of genetic associations offers the potential to direct clinical management in order to prevent inhibitor development and improve clinical care in patients with inhibitors.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DNA and relevant clinical data from properly consented hemophiliac subjects and family members (maximum estimated = 3500) will be provided to the LGD for genotyping and analysis.
Exclusion criteria
No available subjects will be excluded to maximize power.
Time frame: Every six months
National Cancer Institute (NCI)
Nih
Factor VIII Inhibitor Formation: Identifying Predisposing Genetic Factors
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02546622
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
San Diego, California, United States
View Trial DetailsNCT04398628
Anemia, Anemia, Hemolytic
Phoenix, Arizona, United States
View Trial DetailsNCT06820515
Anemia, Anemia, Hemolytic
Hickory, North Carolina, United States
View Trial DetailsNCT07691437
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Trabzon, Turkey (Türkiye)
View Trial Details